INTRODUCTION
Despite declines in new HIV infections in the United States (U.S.), sexual and gender minority (SGM) populations remain disproportionately affected by HIV. 1 Emtricitabine/tenofovir (Truvada™) as pre-exposure prophylaxis (PrEP) is an effective, safe, and important HIV prevention strategy. [2] [3] [4] [5] [6] [7] [8] [9] [10] However, only around 8% of the 1.1 million Americans who could benefit from PrEP are taking the medication. 11 The sequential steps required to achieve protection with PrEP (i.e., PrEP care continuum) are a potential reason for slow uptake; multiple barriers need to be reduced. 8, 12, 13 Research among potential PrEP users identifies awareness and knowledge of PrEP, costs, side effects, PrEP stigma, beliefs about HIV, and access to health care as important factors impacting uptake of PrEP. [14] [15] [16] [17] [18] [19] [20] [21] Findings from open-label trials and demonstration projects have been similar, [22] [23] [24] although research in these contexts has focused on adherence and sexual behavior changes rather than uptake. [25] [26] [27] [28] [29] [30] Others have studied provider barriers to PrEP implementation, finding that provider education is an important aspect of PrEP access. 22, [31] [32] [33] [34] [35] Few studies have examined patient experiences outside of research settings, mainly exploring experiences within specific clinics and programs already designed to deliver PrEP. 22, 27, [36] [37] [38] [39] While these findings are helpful for implementation, little is known about PrEP use in less controlled settings where providers may not be equipped to prescribe PrEP and potential PrEP users may not receive the same level of support. Furthermore, the U.S. Preventive Services Task Force's current draft recommendation statement on PrEP states that clinicians should provide PrEP for patients at high risk of acquiring HIV (Grade A) 40 , which in the future may result in increasing demands for PrEP in primary care settings. We sought to identify barriers and facilitators of PrEP access by examining SGM patient experiences of
Data Analysis
We conducted a thematic analysis using a data-driven inductive approach and constructivist paradigm (i.e., theorized participants' motivations, experiences, and meanings from what they said rather than making inferences about the sociocultural contexts and structural conditions that enabled individual accounts), following the six phases outlined by Braun and Clarke. 41 Coding was conducted at the semantic level and organized with Atlas.ti 7. Three co-authors (CJS, KMA, CN) independently read four transcripts and made notes for coding, then collectively developed a preliminary codebook with detailed descriptions of each code. Two co-authors (CJS and KMA) independently read and coded all transcripts, giving equal attention to each data item. During this process, they met to discuss and reconcile codes, add additional codes as necessary, and resolve discrepancies through consensus. After coding, three co-authors (CJS, KMA, CN) met to determine preliminary themes representing a patterned response, check each theme against other themes, and verify that themes were grounded in the data. Diagramming was used to explore the relationship and connectedness between themes. The full team of academic and community partners met to refine and finalize themes, such that themes were coherent, specific enough to be distinct and general enough to describe patterns observed in multiple responses; name themes; and identify exemplar quotes to ensure the analysis and data matched. 42 
RESULTS

Description of Participants
Participants (N = 27) were 21 to 67 years old (mean 38.0; Table 1 ). Most participants identified as cisgender gay men. Nearly one-third of the sample identified as Latino or multiracial. Income levels varied widely, but all participants had some college education. More than half of participants had private or employer-sponsored insurance. Most participants sought or received PrEP from primary care or infectious disease clinics.
Themes
Participants expressed a range of experiences during interactions with providers and health care systems when seeking, obtaining, and using PrEP. Three overarching themes emerged: the centrality of patient-provider relationships, the necessity of individual advocacy to access PrEP, and the experience of system-level barriers to PrEP access.
Patient-Provider Relationships Are Central to Positive Experiences Around PrEP
Participants described a connection between the quality of the provider relationship and PrEP counseling. Some participants described providers who had created a safe environment to facilitate discussions about sexual health and PrEP. One participant shared, She [provider] was totally cool about everything and just no judgment whatsoever. Everything was very matter of fact, like, BWho do you have sex with?â nd just very casual and she used correct pronouns for me. (P15) Generally, providers who were knowledgeable and wellinformed about PrEP were described as sex positive (having positive attitudes about sex and comfortable with patients' sexuality and sexual behaviors). Participants also shared that having open conversations with their providers about potential HIV risk and sexual health concerns strengthened the patientprovider relationship and comfort participants had with their providers. For example,
The doctor was really affirming, which was also mindblowing because I've never actually had a doctor that has talked to me about sex and risks, in my life… It was just an awesome experience.^(P14) Some participants attributed these strained relationships and poor patient-provider communication to providers' discomfort with their gender identity, sexual identity, or sexual behavior. A participant reflected, I felt like he totally slut shamed me… I really couldn't believe the way that he treated me. And it was so clearly linked to when he noticed that I was a PrEP user, aka, when he noticed I was a gay man. (P3)
Another participant said, I think my trans status sort of threw the doctor for a loop. She almost didn't seem to know quite how to handle it. (P24)
It was also mentioned that participants whose providers were not aware of their gender identity, sexual identity, or sexual behavior would have additional challenges accessing PrEP:
It might be really hard for a person in the closet to ask for PrEP-you first have to come out to your doctor then you have to convince the doctor that PrEP's a good thing, too. (P1)
Because of these experiences with provider discomfort and bias, some participants described difficulties trusting medical providers and systems. For example, When things go wrong, I start questioning, BIs that going to go wrong because they just made a mistake or is it wrong because they don't give a fuck about me?^(P15) Advocacy for PrEP occurred in multiple forms. When participants met with providers who lacked awareness or knowledge of PrEP, participants educated providers about PrEP, prescribing guidelines, and other clinical resources. One participant described, Because of insurance I've had three different providers. And each one of them didn't know about PrEP. So the first one I had to take the guidelines with me so that he would actually prescribe it to me. And then the second one and the third one when I told them I was on Truvada they both asked me if I was HIV positive. (P4) After educating providers, several participants felt that their providers questioned them in uncomfortable ways or with inappropriate skepticism about meeting prescribing criteria and medication adherence. For example, I had to talk quite a bit about why I want to be on Truvada, what I thought it was for, what I knew about it, what I knew it didn't protect against and I pretty much had to convince them that I was adult enough to be on it. (P5)
One participant, a transgender man, described that his provider did not seem to understand why he might be a good candidate for PrEP, and needed to be convinced:
The doctor seemed to think that the type of sex that I was having didn't really warrant going on PrEP. I told her, BWell, I'm a man who has sex with men who I know for a fact have sex with other men, and I have multiple partners, so I am pretty interested in it.^(P24) Finally, prescribing guidelines state that multiple laboratory tests should be done before and during use to identify contraindications. However, participants noted that these tests did not always occur, as described:
[My doctor has] never given me a blood test. He's never tested my liver, and he didn't test to see whether or not I was positive before putting me on. (P2)
After filling a prescription, the impetus remained on patients to manage follow-up labs. One noted, BI still do my own testing. I still have to remind him [provider] when I have to check my kidneys and things like that.^(P4)
Patients Experience Many Systemic Barriers to PrEP Use
Participants reported seeking PrEP through different practice settings and with providers of various specialties (e.g., infectious disease, primary care, nurse practitioner, naturopathic doctor) and described many systemic barriers. These barriers were related to the speed and ease of processes, actual and perceived costs, pharmacies, and follow-up care.
The PrEP continuum was extended when participants had to visit multiple doctors or return to the same doctor more than once for a prescription. One participant described, I told him about the medication… I never heard back. So I contacted him again... I still didn't hear back. I think it was the third appointment where I went in and kind of demanded that something get done. (P13) Participants who lived in rural areas had difficulty finding doctors who would prescribe PrEP and often had to travel long distances for PrEP access: BIf you're in the rural areas they don't have any specialists, so you have to go out of your way.( P1) Even in urban areas, several participants had difficulty connecting to a provider because some health systems only allowed certain providers to prescribe PrEP or did not have a clear policy for whom should prescribe PrEP: BShe [primary care provider {PCP}] wanted him [infectious disease doctor] to prescribe it, and he wanted her to prescribe it.^(P6) For participants who did not currently have a regular provider, initiating care with a provider often resulted in a delay. One participant described, BI called the local doctor group and said, 'I want a doctor' and they told me it was about four months wait.^(P5) Costs served as a barrier to uptake, either because participants could not afford PrEP or had heard PrEP was expensive. One participant noted, BPart of the reason why I waited so long was I didn't have the money to be able to afford the drug.( P23) Similarly, another participant shared, BThe prescription was sitting around for a while since I couldn't cover the copay.^(P16) It was common for participants to report that they had heard from others that the biggest problem in accessing PrEP was the cost. One participant, who was uninsured, described pursuing PrEP and determining that cost would prevent him from accessing the medication:
I'm going to have to incur that cost, which is just daunting and scary. Is a cost going to stop me from doing this thing? And it looks like it is. (P9)
To reduce the burden associated with cost, some participants described applying for and receiving financial support from the manufacturer. Often, they had learned about it through PrEP-focused patient navigators. However, participants reported difficulty accessing the manufacturer's program. Some PrEP users sought to increase awareness of the manufacturer's financial support by discussing it with friends. As one participant shared, BAs soon as I learn that someone is on PrEP, I'll talk to them, 'Oh my god, are you getting reimbursed?' They're like, 'What is that?' So, maybe there is more we can do to help spread the word.^(P17)
Additional difficulties related to cost and access arose when trying to fill PrEP prescriptions at pharmacies. Some participants encountered problems when trying to pay for the medication using insurance; others had challenges applying the manufacturer's financial support. One participant reflected, If I didn't have credit cards I would not be able to afford it [PrEP] because my pharmacy doesn't do the copay card. You have to do a reimbursement that takes about a month to a month and a half to get it. (P11)
Other participants experienced interruptions in medication because their pharmacies did not stock PrEP and they had to wait several days for refills. Several PrEP users tried to avoid these problems by receiving refills by mail. For some, this approach was ideal, but others experienced problems due to strict delivery requirements: BThe fact that they have to ship it to me is very inconvenient because then I either need to have it shipped to my work because that's where I am during the day or stay home because UPS won't leave anything at the door of your apartment.^(P5)
Finally, follow-up care varied widely among participants, including the frequency, content, and delivery mode. Most participants reported receiving regular HIV testing. However, in many cases, participants were primarily responsible for ensuring that testing was done. Some participants attended in-person visits every three to six months, while others never had a follow-up visit. Some described receiving little counseling about PrEP from their providers, while other providers consistently offered risk reduction and condom use counseling at every visit. Participant responses to counseling were mixed; some reported feeling supported while others were not interested. One participant who responded positively to risk reduction counseling shared, BHe reminds me how important condoms are. I say, 'That's really great information and I agree with you 100%. With any new partners I always use condoms.'^(P5) However, the same participant said he would not be interested in adherence counseling because BI feel that that's really something the person taking Truvada should be responsible for.^(P5) Another participant who did not receive adherence and risk reduction counseling said, BI'd like them to offer it so I'd know they're offering it to other people, but I don't need it myself.^(P6)
Many patients reported receiving follow-up care by phone or email, which was generally described as more convenient than in-person, while still sufficient to ask questions and bring up concerns. A number of participants suggested that followup care would be easier if they received reminders when they were due. One participant described, BIt would be awesome if it was like a text message that said, 'If you're taking your pills, you have two weeks left. We've already booked your test, go into any [clinic] and have your blood drawn. Thanks so much.'^(P17)
DISCUSSION
In this study, we explored patient experiences seeking and using PrEP to prevent HIV in practice settings. Participants identified relationships with their providers, self-advocacy, and systemic barriers as key elements to accessing and using PrEP. Patricipants also made suggestions including improving provider engagement with SGM patients, encouraging providers to initiate conversations about PrEP, and increasing awareness of financial assistance.
Our study contributes to the existing literature by examining experiences of PrEP access and use outside of clinical trials and open-label projects during which PrEP is provided for free with regular monitoring. Studying PrEP experiences in practice settings, we were able to examine issues related to patientprovider relationships, medication costs, and coordination between patients, providers, pharmacies, and payers.
In our study, participants received PrEP from infectious disease, primary care, and community-based sexual health clinics. There is on-going discussion about the role of different types of providers in prescribing PrEP, particularly PCPs and infectious disease specialists. [43] [44] [45] [46] [47] PCPs are a preferred source of PrEP for many patients, 48, 49 and increased trust in a PCP is associated with increased PrEP willingness. 50 This corroborates our finding that many participants felt more comfortable discussing sensitive topics with a provider they already knew and trusted. Additionally, it was typically easier and faster for participants to receive PrEP from a PCP, as long as that provider was knowledgeable about PrEP. However, many PCPs lack the knowledge to be comfortable and effective in prescribing and managing PrEP, including providing followup care, as observed in our study and previous research. 47, [51] [52] [53] Several participants in this study accessed PrEP through community-based sexual health clinics, and all described positive experiences. Fewer reports have examined the provision of PrEP in this context. These clinics may represent an additional opportunity to increase PrEP access. Providers at community-based sexual health clinics, including STD clinics, already serve populations at increased risk for HIV and may engage patients with culturally competent and non-judgmental discussions about their sexual health. Some previous studies have described successful PrEP implementation through STD clinics. 22, 36, 49 Further research is needed to understand patients' preferences and experiences in accessing PrEP at STD clinics and the role of provider and organizational factors.
It is possible that negative experiences with providers such as those reported by several of our participants could deter patients from further engaging with providers and become a barrier to accessing other health care. Several participants in our sample feared that negative PrEPseeking experiences might be related to provider discrimination. Increased perception of stigma is associated with decreased utilization of medical care among SGM populations. 54, 55 In contrast, when providers are able to engage positively with patients seeking PrEP, this interaction can be an avenue to encourage preventative care among patients who have lower health care-seeking behaviors.
Similar to our findings, participants in other real-world studies found cost to be a challenge for patients. In a primary care clinic, both perceived cost and actual cost were important barriers to PrEP access, with knowledge about payment assistance programs being particularly vital to continuing PrEP if one's health insurance or financial situation changed. 38 While few participants in a PrEP program at one STD clinic encountered payment issues, clinic staff dedicated considerable time to helping navigate medication assistance programs. 37 It appears that support in obtaining payment assistance is critical to PrEP uptake and retention. 37, 38, 56 Findings from this study should be considered in light of several limitations. Most participants were white cisgender gay men; however, this proportion mirrors the state's HIV epidemiology. We found that transgender and genderqueer participants reported experiences that were more difficult due to gender identity-related discrimination but were not thematically different than the experiences of cisgender participants. The experiences of cisgender women and heterosexual adults may differ. It is also possible that participants in this study had more negative experiences than those not in the study. Only one participant was uninsured; those without insurance are likely to face challenges in accessing PrEP. Additionally, all participants had at least some college education. Potential PrEP users with a different educational background may face additional barriers. Most participants resided in a single urban BBased on the sexual history we discussed, PrEP seems like it might be a good fit for you.Î f PrEP is not indicated for the patient at this time, let them know that it is available if their sexual practices change in the future. Concern about cost and lack of information about payment assistance options Let patients know that PrEP can be affordable for most people. Give patients information about medication assistance programs, especially financial support available through the manufacturer (https://www.gileadadvancingaccess.com). If the clinic or health system has patient navigators, resource referral specialists, or other staff who can assist in applying for payment assistance, refer patients to these staff. If not, local AIDS service organizations may be able to assist patients to apply for insurance or PrEP financial assistance.
area. Participants in other cities or rural areas may have different PrEP access experiences. For instance, at the time of interviews, Medicaid programs in the Portland metropolitan area fully cover PrEP, but this policy is not true for all of Oregon.
Despite these limitations, our study has several important implications. Providers can use these findings to provide responsive, patient-centered care. Patients want providers who are non-judgmental and comfortable having conversations about sexual health and sexuality (see Table 2 for examples of communication techniques). Ensuring that providers are taking complete sexual histories in a culturally appropriate way is a key step to increase PrEP access. Additionally, participants want providers to be knowledgeable about PrEP and discuss its effectiveness, side effects, and other considerations. Providers, especially PCPs, should be educated about PrEP so that they can counsel patients about PrEP, accurately follow prescribing guidelines, and reduce the risk of undetected and untreated complications. Providers have endorsed the suggestion of increased PrEP training. 47 PCPs should also be encouraged to initiate conversations with their patients about PrEP, as our research agrees with previous studies showing that patients bear the burden of introducing this topic. 47, 57 Crucial next steps include developing and testing interventions to improve patient-provider relationships, especially around sexual health.
Additionally, providers and social and health service organizations could do more to connect potential PrEP patients to health care systems. Providing support to improve affordability (e.g., assistance to enroll in health insurance, insurance subsidy programs, and medication support programs); identifying providers experienced in PrEP care; and letting patients know what to expect in conversations with doctors would ease the process of accessing PrEP. It appears that PrEP-focused or PrEP-knowledgeable patient navigators are helping fulfill this role in practice settings across the county and future research could better understand their impacts in improving uptake. 58 On a systems level, there are several opportunities for improvement. Health care clinics can routinize PrEP prescribing, including implementing measures in electronic health record systems to identify potential PrEP candidates and cue for lab orders and follow-up care. Improved coordination between pharmacies, insurance companies, and the manufacturer's financial support program may help patients reduce cost barriers and interruptions in PrEP access. Further research could explore other pharmacy-related improvements, such as enlisting pharmacists as an additional source of PrEP counseling. 59 Improving patient-provider relationships, increasing provider knowledge of PrEP, and removing systemic barriers are key elements to improve successful PrEP access and use among SGM communities that are disproportionately affected by HIV. Reducing HIV disparities with PrEP will require additional efforts by providers and health care systems to ensure that PrEP is reaching those who need it.
